July 5, 2016
Curetis Appoints Christopher M. Bernard as Chief Executive Officer of Newly-Formed U.S. Subsidiary – Former Chief Commercial Officer of Epic Sciences brings valuable experience in sales, […]
June 28, 2016
Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections – Last patient enrolled in prospective arm of IVD trial – More […]
June 20, 2016
Curetis has received great results for its diagnostic kit. This new technology to detect sepsis is delivering the same results as standard tests, but it’s faster by 24 […]
June 17, 2016
Jun 16, 2016 | NEW YORK (GenomeWeb) – Curetis said today that it has received the CE-IVD mark for its Unyvero BCU Blood Culture Application Cartridge […]
June 16, 2016
USPSTF recognizes Epi proColon as the only blood-based colorectal cancer screening test Convenient and minimal-invasive blood-based testing contributes to USPSTF´s goal of higher screening participation USPSTF […]
June 6, 2016
Curetis and Axonlab Sign Multi-Market European Distribution Agreement – Axonlab to become exclusive distributor for all Unyvero products in selected Central and Eastern European countries Amsterdam, […]
May 20, 2016
Curetis Publishes First Quarter 2016 Business and Financial Update – Worldwide commercial expansion and US FDA trial on track – Installed base of Unyvero Analyzers increased […]
May 16, 2016
You Can’t Stop Seattle – that is the message Delta is sending with the launch of an ad campaign targeting Delta’s growing West Coast hub. http://news.delta.com/you-can-t-stop-delta-seattle-launch-ad-campaign
May 9, 2016
LabCorp Announces the Launch of the Epi proColon® Test for Colorectal Cancer Screening First FDA-Approved Blood-Based Colorectal Cancer Test Offers Alternative for Patients Non-Compliant with Existing […]
